|Articles|April 21, 2016
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
Advertisement
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO
2
How Basket-Trials are Reshaping Drug Development Timelines
3
Parabilis Reaches $3.7 Billion Market Cap on Frist Day Listed on NASDAQ
4
The New Capital of Care in Rare Disease
5